Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: An endothelin receptor antagonist improves the peak PETCO2

Hirashiki, Akihiro; Adachi, Shiro; Nakano, Yoshihisa; Kono, Yuji;
Shimazu, Shuzo; Shimizu, Shinya; Morimoto, Ryota; Okumura, Takahiro;
Takeshita, Kyosuke; Yamada, Sumio; Murohara, Toyoaki; Kondo, Takahisa.

Life Sciences, November 2014, Vol. 118 Issue: Number 2 p397-403, 7p;
Abstract: The 6-min walking distance is often used for assessing the
exercise capacity under the treatment with an endothelin receptor
antagonist (ERA) in patients with chronic thromboembolic pulmonary
hypertension (CTEPH). The cardiopulmonary exercise testing (CPX) was
reported to be more useful for the patients with pulmonary arterial
hypertension (PAH), however, few reports exist in patients with
inoperable CTEPH. The aim of this study was to investigate the effects
of an oral dual ERA, bosentan, on exercise capacity using CPX in
patients with PAH and inoperable CTEPH.;